Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Rocket Pharmaceuticals Inc (RCKT)
Rocket Pharmaceuticals Inc (RCKT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,371,182
  • Shares Outstanding, K 90,159
  • Annual Sales, $ 0 K
  • Annual Income, $ -221,860 K
  • 60-Month Beta 1.02
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.77
Trade RCKT with:

Options Overview Details

View History
  • Implied Volatility 54.80% ( -1.49%)
  • Historical Volatility 60.81%
  • IV Percentile 7%
  • IV Rank 23.86%
  • IV High 114.72% on 12/22/22
  • IV Low 36.02% on 09/11/23
  • Put/Call Vol Ratio 0.21
  • Today's Volume 63
  • Volume Avg (30-Day) 313
  • Put/Call OI Ratio 0.44
  • Today's Open Interest 14,627
  • Open Int (30-Day) 13,953

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.79
  • Number of Estimates 7
  • High Estimate -0.69
  • Low Estimate -0.87
  • Prior Year -0.92
  • Growth Rate Est. (year over year) +14.13%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.85 +48.38%
on 11/10/23
26.61 -0.47%
on 12/07/23
+6.92 (+35.33%)
since 11/08/23
3-Month
15.27 +73.44%
on 09/12/23
26.61 -0.47%
on 12/07/23
+10.85 (+69.34%)
since 09/08/23
52-Week
14.89 +77.87%
on 08/21/23
26.61 -0.47%
on 12/07/23
+7.89 (+42.39%)
since 12/08/22

Most Recent Stories

More News
Better Gene Editing Stock: Intellia Therapeutics vs. Rocket Pharmaceuticals

Rocket could launch its medicines sooner, but Intellia is aiming for larger markets.

NTLA : 29.74 (-0.13%)
RCKT : 26.09 (-0.80%)
Rocket Pharmaceuticals Stock Is Blasting Off, but Here's Why You Should Tread Carefully

Its near-term risks are subtle but bigger than their flying stock price might indicate.

RCKT : 26.09 (-0.80%)
Betting on Rocket Pharmaceuticals (RCKT)? Check the Options Flow Data First.

Although Rocket Pharmaceuticals lived up to its name on Wednesday due to an encouraging clinical trial development, the big dogs have some questions about RCKT stock.

RCKT : 26.09 (-0.80%)
RCKT|20231020|17.50C : N/A (unch)
RCKT|20240119|25.00C : 2.65 (unch)
Why Shares of Rocket Pharmaceuticals Are Taking Off on Wednesday

The late-stage pharmaceutical company said it had reached an agreement with the Food and Drug Administration regarding a phase 2 trial for a Danon disease therapy.

RCKT : 26.09 (-0.80%)
Stocks Tread Water Before the Open as U.S. Inflation Data Looms

September S&P 500 futures (ESU23) are down -0.02%, and September Nasdaq 100 E-Mini futures (NQU23) are down -0.04% this morning as market participants geared up for a key U.S. consumer inflation report...

ESU23 : 4,491.72s (-0.32%)
NQU23 : 15,435.20s (-0.28%)
ORCL : 112.46 (-0.36%)
AAP : 55.73 (-0.92%)
AAPL : 194.72 (+0.23%)
WRK : 41.20 (+0.56%)
AV-.LN : 428.400 (+0.12%)
WKHS : 0.4034 (-0.12%)
RCKT : 26.09 (-0.80%)
F : 11.02 (+1.85%)
SQSP : 27.45 (-1.15%)
EIGR : 0.3066 (-4.16%)
Rocket Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Progress

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today...

RCKT : 26.09 (-0.80%)
Rocket Pharmaceuticals to Participate in the Bank of America Securities 2023 Healthcare Conference

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today...

RCKT : 26.09 (-0.80%)
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today...

RCKT : 26.09 (-0.80%)
Rocket Pharmaceuticals Announces Leadership Expansion to Support Company on Evolution Towards Commercial Stage

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today...

RCKT : 26.09 (-0.80%)
Rocket Pharmaceuticals to Participate in the 43rd Annual Cowen Health Care Conference

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today...

RCKT : 26.09 (-0.80%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Rocket Pharmaceuticals, Inc. is an emerging, clinical-stage biotechnology company. It focused on developing first-in-class gene therapy treatment options for rare, undertreated diseases. Rocket Pharmaceuticals Inc., formerly known as Inotek Pharmaceuticals Corporation, is based in LEXINGTON, United States....

See More

Key Turning Points

3rd Resistance Point 27.70
2nd Resistance Point 27.15
1st Resistance Point 26.73
Last Price 26.09
1st Support Level 25.76
2nd Support Level 25.21
3rd Support Level 24.79

See More

52-Week High 26.61
Last Price 26.09
Fibonacci 61.8% 22.13
Fibonacci 50% 20.75
Fibonacci 38.2% 19.37
52-Week Low 14.89

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar